IMMUNO-TET

Part 1: Retrospective, multicentre, constitutional and somatic molecular profiling study of TETs patients.;Part 2: Prospective, open-label, multicenter, low-risk, low-constraint study (category 2 research involving humans) to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with TETs.;ID-RCB Number : 2022-A01299-34;IMMUNO-TET À Version n¦1.0 À 30/06/2022 2 / 6;Part 3: Prospective study to assess the feasibility of developing patient-derived xenograft (PDX) mouse models from TETs.;Primary objectives of the study :;1. Feasibility of molecular characterisation of TETs:;a) somatic molecular characterisation of TETs:;À On the one hand in the framework of RNA sequencing of epithelial tumour cells (prospective project),;À As well as in the context of the sequencing of the exome of these tumours (retrospective project).;b) constitutional characterisation of TETs:;À With the technique of the Whole Exome Sequencing (WES) on blood samples of patients with TETs (prospective project).;2. Feasibility of characterising the immune environment of TETs:;À Single-cell RNA sequencing of TET immune environment cells,;À Phenotyping of cells in the immune environment of TETs.;3. Feasibility of establishing a patient-derived xenograft mouse model:;À Initial culture of histological subtypes,;À Transfer to mouse models,;À Assessment of tumour response to different treatments delivered.